<?xml version='1.0' encoding='utf-8'?>
<document id="24595680"><sentence text="4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys."><entity charOffset="0-21" id="DDI-PubMed.24595680.s1.e0" text="4β-Hydroxycholesterol" /></sentence><sentence text="It has been proposed that in humans 4β-hydroxycholesterol is formed mainly by CYP3A-catalyzed metabolism of cholesterol and thus may serve as an endogenous marker for CYP3A activity"><entity charOffset="36-57" id="DDI-PubMed.24595680.s2.e0" text="4β-hydroxycholesterol" /><entity charOffset="108-119" id="DDI-PubMed.24595680.s2.e1" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.24595680.s2.e0" e2="DDI-PubMed.24595680.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24595680.s2.e0" e2="DDI-PubMed.24595680.s2.e1" /></sentence><sentence text=" The cynomolgus monkey is widely used as one of the nonrodent preclinical safety species in pharmaceutical research" /><sentence text=" In the current study, the potential application of 4β-hydroxycholesterol as an endogenous biomarker of CYP3A in response to drug treatment was evaluated in cynomolgus monkeys"><entity charOffset="52-73" id="DDI-PubMed.24595680.s4.e0" text="4β-hydroxycholesterol" /></sentence><sentence text=" Following multiple oral administration of rifampicin (a known CYP3A inducer) at 15 mg/kg/d in cynomolgus monkeys, the mean serum 4β-hydroxycholesterol levels increased 4-fold from the baseline of 55"><entity charOffset="43-53" id="DDI-PubMed.24595680.s5.e0" text="rifampicin" /><entity charOffset="130-151" id="DDI-PubMed.24595680.s5.e1" text="4β-hydroxycholesterol" /><pair ddi="false" e1="DDI-PubMed.24595680.s5.e0" e2="DDI-PubMed.24595680.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24595680.s5.e0" e2="DDI-PubMed.24595680.s5.e1" /></sentence><sentence text="3 ± 21" /><sentence text="7 to 221 ± 53" /><sentence text="4 ng/ml" /><sentence text=" The mean concentration ratios of 4β-hydroxycholesterol to cholesterol increased 5-fold"><entity charOffset="34-55" id="DDI-PubMed.24595680.s9.e0" text="4β-hydroxycholesterol" /><entity charOffset="59-70" id="DDI-PubMed.24595680.s9.e1" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.24595680.s9.e0" e2="DDI-PubMed.24595680.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24595680.s9.e0" e2="DDI-PubMed.24595680.s9.e1" /></sentence><sentence text=" The data suggest that 4β-hydroxycholesterol formation from cholesterol metabolism was induced by rifampicin treatment in monkeys"><entity charOffset="23-44" id="DDI-PubMed.24595680.s10.e0" text="4β-hydroxycholesterol" /><entity charOffset="60-71" id="DDI-PubMed.24595680.s10.e1" text="cholesterol" /><entity charOffset="98-108" id="DDI-PubMed.24595680.s10.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.24595680.s10.e0" e2="DDI-PubMed.24595680.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24595680.s10.e0" e2="DDI-PubMed.24595680.s10.e1" /><pair ddi="false" e1="DDI-PubMed.24595680.s10.e0" e2="DDI-PubMed.24595680.s10.e2" /><pair ddi="false" e1="DDI-PubMed.24595680.s10.e1" e2="DDI-PubMed.24595680.s10.e1" /><pair ddi="false" e1="DDI-PubMed.24595680.s10.e1" e2="DDI-PubMed.24595680.s10.e2" /></sentence><sentence text=" This observation correlated with the metabolism of midazolam (a probe substrate of CYP3A activity) monitored in the same study"><entity charOffset="52-61" id="DDI-PubMed.24595680.s11.e0" text="midazolam" /></sentence><sentence text=" The serum exposure (area under the curve) of midazolam was markedly decreased by ∼95%, confirming the induction of CYP3A catalytic activity by rifampicin treatment in monkeys"><entity charOffset="46-55" id="DDI-PubMed.24595680.s12.e0" text="midazolam" /><entity charOffset="144-154" id="DDI-PubMed.24595680.s12.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.24595680.s12.e0" e2="DDI-PubMed.24595680.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24595680.s12.e0" e2="DDI-PubMed.24595680.s12.e1" /></sentence><sentence text=" The formation of 4β-hydroxycholesterol from cholesterol was specifically mediated by recombinant cynomolgus CYP3A8 and CYP3A5"><entity charOffset="18-39" id="DDI-PubMed.24595680.s13.e0" text="4β-hydroxycholesterol" /><entity charOffset="45-56" id="DDI-PubMed.24595680.s13.e1" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.24595680.s13.e0" e2="DDI-PubMed.24595680.s13.e0" /><pair ddi="false" e1="DDI-PubMed.24595680.s13.e0" e2="DDI-PubMed.24595680.s13.e1" /></sentence><sentence text=" The Km values of CYP3A8 and CYP3A5 for 4β-hydroxycholesterol formation from cholesterol were 204 and 104 μM, respectively, and Vmax values were 0"><entity charOffset="40-61" id="DDI-PubMed.24595680.s14.e0" text="4β-hydroxycholesterol" /><entity charOffset="77-88" id="DDI-PubMed.24595680.s14.e1" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.24595680.s14.e0" e2="DDI-PubMed.24595680.s14.e0" /><pair ddi="false" e1="DDI-PubMed.24595680.s14.e0" e2="DDI-PubMed.24595680.s14.e1" /></sentence><sentence text="600 and 0" /><sentence text="310 pg/pmol/min, respectively" /><sentence text=" The results suggest that 4β-hydroxycholesterol can be used as an endogenous biomarker to identify strong CYP3A inducers in cynomolgus monkeys, which may help to evaluate drug-drug interaction potential of drug candidates in preclinical settings"><entity charOffset="26-47" id="DDI-PubMed.24595680.s17.e0" text="4β-hydroxycholesterol" /></sentence><sentence text=" " /></document>